Advances in neuroimaging and genomics have enabled unprecedented insights into the biological underpinnings of neuropsychiatric disorders; however, integrating heterogeneous, high-dimensional datasets remains a significant analytical challenge. This paper explores quantum neuroinformatics for multi-modal brain imaging, focusing on the integration of functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and genomic data to model complex neuropsychiatric phenotypes. By leveraging hybrid quantum–classical machine learning frameworks, the study examines how quantum-enhanced feature mapping, probabilistic modeling, and high-dimensional optimization can improve the fusion and interpretation of multimodal datasets. The analysis evaluates the potential of quantum algorithms to capture nonlinear interactions across neural, temporal, and genetic domains, while also addressing computational and hardware limitations associated with the Noisy Intermediate-Scale Quantum (NISQ) era. The findings suggest that quantum neuroinformatics may offer a novel pathway for advancing precision psychiatry by enabling more accurate phenotypic classification, biomarker discovery, and personalized treatment strategies.
Advances in neuroimaging and genomics have enabled unprecedented insights into the biological underpinnings of neuropsychiatric disorders; however, integrating heterogeneous, high-dimensional datasets remains a significant analytical challenge. This paper explores quantum neuroinformatics for multi-modal brain imaging, focusing on the integration of functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and genomic data to model complex neuropsychiatric phenotypes. By leveraging hybrid quantum–classical machine learning frameworks, the study examines how quantum-enhanced feature mapping, probabilistic modeling, and high-dimensional optimization can improve the fusion and interpretation of multimodal datasets. The analysis evaluates the potential of quantum algorithms to capture nonlinear interactions across neural, temporal, and genetic domains, while also addressing computational and hardware limitations associated with the Noisy Intermediate-Scale Quantum (NISQ) era. The findings suggest that quantum neuroinformatics may offer a novel pathway for advancing precision psychiatry by enabling more accurate phenotypic classification, biomarker discovery, and personalized treatment strategies.
Advances in neuroimaging and genomics have enabled unprecedented insights into the biological underpinnings of neuropsychiatric disorders; however, integrating heterogeneous, high-dimensional datasets remains a significant analytical challenge. This paper explores quantum neuroinformatics for multi-modal brain imaging, focusing on the integration of functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and genomic data to model complex neuropsychiatric phenotypes. By leveraging hybrid quantum–classical machine learning frameworks, the study examines how quantum-enhanced feature mapping, probabilistic modeling, and high-dimensional optimization can improve the fusion and interpretation of multimodal datasets. The analysis evaluates the potential of quantum algorithms to capture nonlinear interactions across neural, temporal, and genetic domains, while also addressing computational and hardware limitations associated with the Noisy Intermediate-Scale Quantum (NISQ) era. The findings suggest that quantum neuroinformatics may offer a novel pathway for advancing precision psychiatry by enabling more accurate phenotypic classification, biomarker discovery, and personalized treatment strategies.
Multi-modal biomedical imaging has become central to modern diagnostics, offering complementary anatomical, functional, and molecular information through modalities such as MRI, CT, PET, ultrasound, and optical imaging. Yet integrating these heterogeneous datasets remains computationally demanding due to differences in spatial resolution, noise profiles, acquisition dynamics, and high-dimensional feature distributions. This paper investigates AI–quantum hybrid diagnostic systems as an emerging paradigm for multimodal image fusion, reconstruction, and disease classification. By combining deep learning architectures with quantum-enhanced algorithms—including variational quantum circuits, quantum feature encoders, and quantum kernel methods—the hybrid framework aims to accelerate image processing, improve cross-modal consistency, and enhance diagnostic precision. The analysis highlights advancements in quantum-accelerated denoising, multi-modal registration, probabilistic inference, and high-dimensional pattern recognition. It also evaluates workflow integration challenges, such as NISQ-era noise, hardware scalability, and clinical interpretability. Overall, AI–quantum hybrid systems represent a promising frontier in medical imaging, offering potential improvements in speed, sensitivity, and personalized diagnostic accuracy.
Abstract Psychiatric disorders such as attention deficit hyperactivity disorder, schizophrenia, and bipolar disorder are notoriously difficult to distinguish on neuroimaging alone, owing to overlapping symptom profiles and heterogeneous neurobiological substrates. Conventional machine learning classifiers applied to structural MRI and electroencephalography data have shown modest discriminative performance and, more critically, tend to produce poorly calibrated probability estimates that limit their utility in clinical decision-making. We present a dual-pipeline framework in which quantum kernel support vector machines are applied independently to MRI-derived morphometric features and to EEG spectral representations, followed by rigorous post-hoc calibration and interpretability analyses. On the UCLA Consortium for Neuropsychiatric Phenomics dataset, a 4-qubit quantum kernel SVM achieved an AUC of 0.957 and a Matthews correlation coefficient of 0.679 for ADHD versus control discrimination, while a tuned classical radial basis function SVM performed at chance (AUC=0.497). For EEG-based emotion and cognitive state classification, a hybrid quantum-classical kernel outperformed both its pure quantum and classical counterparts (AUC=0.841 versus 0.824 and 0.812, respectively). Temperature scaling reduced expected calibration error by 85% for the MRI pipeline and by 49% for the EEG pipeline. Multimodal fusion of the two quantum kernel Gram matrices yielded an ECE of 0.0075, the lowest observed across all experimental configurations. Gradient-weighted class activation mapping and Shapley additive explanations recovered neurobiologically established signatures of ADHD and psychotic disorder in prefrontal, cingulate, and basal ganglia regions, lending biological credibility to the learned representations. Taken together, these results indicate that quantum kernel methods can confer genuine advantages over classical baselines in small-sample neuroimaging settings, and that the resulting models can be made reliable enough for clinical deployment through standard calibration procedures.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.
Brain imaging is a critical tool in mental health diagnostics, particularly for detecting anomalies associated with behavioral disorders, anxiety, depression, and neuropsychiatric conditions. Traditional deep learning approaches, such as Convolutional Neural Networks (CNNs), have shown promise in analyzing functional Magnetic Resonance Imaging (fMRI), but they often suffer from computational limitations, feature extraction inefficiencies, and generalization issues. Quantum Machine Learning (QML) offers a transformative solution by enhancing feature representation, improving classification accuracy, and exploiting the power of quantum computation for large-scale medical imaging datasets. In this paper, we explored the potential of quantum models for detecting anomalies in brain imaging. Using the UCLA Consortium for Neuropsychiatric Phenomics dataset, we compared quantum models, including the Variational Quantum Classifier (VQC), Quantum Convolutional Neural Network (QCNN), and Quantum Support Vector Machine (QSVM), with classical models like CNNs and the Support Vector Machine (SVM). Our results revealed that QSVM and VQC outperformed classical models, both achieving 92% accuracy and perfect recall (100%), making them highly effective at identifying positive cases-a critical requirement in clinical diagnostics. QCNN, while less accurate at 74%, still showed strong precision (90%) and an F1score of 85%, highlighting its potential where avoiding false positives is key. Classical models, in comparison, performed moderately well: SVM reached 87% accuracy and CNN achieved 83%, but both had lower precision and F 1 -scores, suggesting less consistent performance. These findings suggest that quantum models, especially VQC and QSVM, offer a promising advantage in neuroimaging-based mental health diagnostics.
Multi-omics integration has become a cornerstone of personalized medicine, enabling researchers to connect genomic, transcriptomic, proteomic, metabolomic, and epigenomic data to reveal complex biological mechanisms and individualized disease signatures. However, the extreme dimensionality, heterogeneity, and nonlinear interactions across omics layers challenge even the most advanced classical machine learning methods. Quantum Machine Learning (QML) offers a powerful alternative by exploiting quantum superposition, entanglement, and high-dimensional feature embeddings to model multi-omics interactions more efficiently. This study proposes a hybrid quantum–classical framework that combines quantum kernel estimation, variational quantum classifiers, and quantum-enhanced feature fusion networks to generate integrative biological signatures for precision diagnostics. Simulation results using benchmark multi-omics datasets demonstrate improved classification accuracy, enhanced sensitivity to weak biological signals, and reduced computational overhead compared to classical baselines. These findings highlight the potential of QML to accelerate multi-omics insights and pave the way toward truly personalized, predictive healthcare.